BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 30089619)

  • 1. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer.
    Touat M; Maisonobe T; Knauss S; Ben Hadj Salem O; Hervier B; Auré K; Szwebel TA; Kramkimel N; Lethrosne C; Bruch JF; Laly P; Cadranel J; Weiss N; Béhin A; Allenbach Y; Benveniste O; Lenglet T; Psimaras D; Stenzel W; Léonard-Louis S
    Neurology; 2018 Sep; 91(10):e985-e994. PubMed ID: 30089619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical and histopathological features of immune checkpoint inhibitor-related myositis in patients with advanced non-small cell lung cancer].
    Jiang JJ; Li YQ; Gu YY
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jan; 45(1):47-52. PubMed ID: 35000305
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
    Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD1 pathway in immune-mediated myopathies: Pathogenesis of dysfunctional T cells revisited.
    Knauss S; Preusse C; Allenbach Y; Leonard-Louis S; Touat M; Fischer N; Radbruch H; Mothes R; Matyash V; Böhmerle W; Endres M; Goebel HH; Benveniste O; Stenzel W
    Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e558. PubMed ID: 31044146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
    Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
    Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
    Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
    Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
    Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory myopathy associated with PD-1 inhibitors.
    Seki M; Uruha A; Ohnuki Y; Kamada S; Noda T; Onda A; Ohira M; Isami A; Hiramatsu S; Hibino M; Nakane S; Noda S; Yutani S; Hanazono A; Yaguchi H; Takao M; Shiina T; Katsuno M; Nakahara J; Matsubara S; Nishino I; Suzuki S
    J Autoimmun; 2019 Jun; 100():105-113. PubMed ID: 30862448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
    Vicino A; Hottinger AF; Latifyan S; Boughdad S; Becce F; Prior JO; Kuntzer T; Brouland JP; Dunet V; Obeid M; Théaudin M
    J Neurol; 2024 Apr; 271(4):1947-1958. PubMed ID: 38141128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors (ICIs)-related ocular myositis.
    Garibaldi M; Calabrò F; Merlonghi G; Pugliese S; Ceccanti M; Cristiano L; Tartaglione T; Petrucci A
    Neuromuscul Disord; 2020 May; 30(5):420-423. PubMed ID: 32387281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
    Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
    Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune targets of heart and skeletal muscles in myasthenia gravis.
    Suzuki S; Utsugisawa K; Yoshikawa H; Motomura M; Matsubara S; Yokoyama K; Nagane Y; Maruta T; Satoh T; Sato H; Kuwana M; Suzuki N
    Arch Neurol; 2009 Nov; 66(11):1334-8. PubMed ID: 19752287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies.
    Liewluck T; Kao JC; Mauermann ML
    J Immunother; 2018 May; 41(4):208-211. PubMed ID: 29200081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.
    Kadota H; Gono T; Shirai Y; Okazaki Y; Takeno M; Kuwana M
    Curr Rheumatol Rep; 2019 Feb; 21(4):10. PubMed ID: 30790071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
    Moreira A; Loquai C; Pföhler C; Kähler KC; Knauss S; Heppt MV; Gutzmer R; Dimitriou F; Meier F; Mitzel-Rink H; Schuler G; Terheyden P; Thoms KM; Türk M; Dummer R; Zimmer L; Schröder R; Heinzerling L
    Eur J Cancer; 2019 Jan; 106():12-23. PubMed ID: 30453170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myasthenia Gravis and Myositis(PD-1 Myopathy)].
    Suzuki S
    Gan To Kagaku Ryoho; 2020 Feb; 47(2):219-223. PubMed ID: 32381950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment.
    Patel NS; Oury A; Daniels GA; Bazhenova L; Patel SP
    Oncologist; 2018 Oct; 23(10):1236-1241. PubMed ID: 29769383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died.
    Aschman T; Schneider J; Greuel S; Meinhardt J; Streit S; Goebel HH; Büttnerova I; Elezkurtaj S; Scheibe F; Radke J; Meisel C; Drosten C; Radbruch H; Heppner FL; Corman VM; Stenzel W
    JAMA Neurol; 2021 Aug; 78(8):948-960. PubMed ID: 34115106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature.
    Nakagomi Y; Tajiri K; Shimada S; Li S; Inoue K; Murakata Y; Murata M; Sakai S; Sato K; Ieda M
    Front Pharmacol; 2022; 13():884776. PubMed ID: 35645839
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune checkpoint inhibitor-induced musculoskeletal manifestations.
    Angelopoulou F; Bogdanos D; Dimitroulas T; Sakkas L; Daoussis D
    Rheumatol Int; 2021 Jan; 41(1):33-42. PubMed ID: 32743706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.